iconiifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Windlas Biotech posts single-digit growth numbers in Q1FY23; stock slips ~2%

5 Aug 2022 , 03:18 PM

Consolidated EBITDA came in at Rs13.8 crore in Q1FY23 as compared to Rs12.4 crore in Q1FY22.
Windlas Biotech Limited, one of India's top five players in the domestic pharmaceutical formulations CDMO industry, released its audited financials for the quarter ended June 30, 2022.

Company’s consolidated revenue from operations stood at Rs119.9 crore in Q1FY23 as compared to Rs111 crore in Q1FY22, clocking a growth of 8.1% yoy.

Consolidated EBITDA came in at Rs13.8 crore in Q1FY23 as compared to Rs12.4 crore in Q1FY22, up by 11.4% on a y-o-y basis. It achieved an EBITDA Margin of 11.5%.

PAT stood at Rs9.80 crore in Q1FY23 as compared to Rs6.7 crore in the previous corresponding quarter, registering a growth of 46.6% yoy. PAT Margin for Q1FY23 came in at 8.2%.

Windlas' Q1FY23 revenue for the CDMO vertical remained largely stable at Rs94.8 crore, contributing about 79% of the consolidated revenue. While Q1FY23 revenue for the Trade Generics vertical was reported at Rs21.4 crore, up 73.2% yoy, contributing about 18% of consolidated revenue.

Exports vertical contributed approximately 2% for Q1FY23 to the consolidated revenue.

CDMO and Export verticals registered a decline of 0.9% and 12.6% yoy in revenue for Q1FY23, respectively.

At around 3.15 PM, Windlas was trading 1.97% lower at Rs217, against previous close of Rs221.35 on NSE. So far, it hit intraday high and low of Rs224.50 and Rs217 respectively.

Related Tags

  • Windlas Biotech
  • WindlasBiotechNews
  • WindlasBiotechNewsToday
  • WindlasBiotechResults
  • WindlasBiotechShare
  • WindlasBiotechSharePrice
  • WindlasBiotechStock
sidebar mobile


19 Feb 2024   |   09:29 AM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.